JP5685773B2 - 血管新生および創傷治癒活性がある薬剤 - Google Patents

血管新生および創傷治癒活性がある薬剤 Download PDF

Info

Publication number
JP5685773B2
JP5685773B2 JP2010523239A JP2010523239A JP5685773B2 JP 5685773 B2 JP5685773 B2 JP 5685773B2 JP 2010523239 A JP2010523239 A JP 2010523239A JP 2010523239 A JP2010523239 A JP 2010523239A JP 5685773 B2 JP5685773 B2 JP 5685773B2
Authority
JP
Japan
Prior art keywords
crystallin
protein
wound
bovine
lens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010523239A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010538020A (ja
JP2010538020A5 (enExample
Inventor
ジョンソン、ケルン
バスデヴァマーシー、マドゥスダン
Original Assignee
ミート アンド ライブストック オーストラリア リミテッド
ミート アンド ライブストック オーストラリア リミテッド
キャラハン イノベーション リサーチ リミテッド
キャラハン イノベーション リサーチ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2007904857A external-priority patent/AU2007904857A0/en
Application filed by ミート アンド ライブストック オーストラリア リミテッド, ミート アンド ライブストック オーストラリア リミテッド, キャラハン イノベーション リサーチ リミテッド, キャラハン イノベーション リサーチ リミテッド filed Critical ミート アンド ライブストック オーストラリア リミテッド
Publication of JP2010538020A publication Critical patent/JP2010538020A/ja
Publication of JP2010538020A5 publication Critical patent/JP2010538020A5/ja
Application granted granted Critical
Publication of JP5685773B2 publication Critical patent/JP5685773B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2010523239A 2007-09-07 2008-09-05 血管新生および創傷治癒活性がある薬剤 Expired - Fee Related JP5685773B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2007904857 2007-09-07
AU2007904857A AU2007904857A0 (en) 2007-09-07 Agents with angiogenic and wound healing activity
PCT/AU2008/001319 WO2009029991A1 (en) 2007-09-07 2008-09-05 Agents with angiogenic and wound healing activity

Publications (3)

Publication Number Publication Date
JP2010538020A JP2010538020A (ja) 2010-12-09
JP2010538020A5 JP2010538020A5 (enExample) 2011-10-20
JP5685773B2 true JP5685773B2 (ja) 2015-03-18

Family

ID=40428369

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010523239A Expired - Fee Related JP5685773B2 (ja) 2007-09-07 2008-09-05 血管新生および創傷治癒活性がある薬剤

Country Status (6)

Country Link
US (1) US8404644B2 (enExample)
EP (2) EP2407175A1 (enExample)
JP (1) JP5685773B2 (enExample)
AU (1) AU2008295449A1 (enExample)
NZ (1) NZ583803A (enExample)
WO (1) WO2009029991A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2407175A1 (en) * 2007-09-07 2012-01-18 Meat & Livestock Australia Limited Agents with angiogenic and wound healing activity
EP2512492A1 (en) 2009-12-14 2012-10-24 University of Massachusetts Methods of inhibiting cataracts and presbyopia
AU2012210013C1 (en) 2011-01-26 2017-06-01 Megmilk Snow Brand Co., Ltd. Sense-improving agent
WO2013073968A2 (en) * 2011-09-12 2013-05-23 Industrial Research Limited Agents for modulation of cell signalling
JP2014005254A (ja) * 2012-06-26 2014-01-16 Bfsr:Kk 熱傷由来全身性炎症反応症候群の予防外用薬
MX366115B (es) 2013-03-14 2019-06-27 Univ Massachusetts Metodos para inhibir cataratas y presbicia.
KR20170040648A (ko) * 2015-10-05 2017-04-13 차의과학대학교 산학협력단 당뇨병성 족부궤양의 예방 또는 치료용 약학 조성물
CR20180294A (es) 2015-11-13 2018-08-10 Univ Massachusetts Moléculas bifuncionales que contienen peg para uso en la inhibición de cataratas y presbicia
US20220088265A1 (en) * 2019-02-08 2022-03-24 Manmeet Kaur Biomaterials and methods related thereto

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2187482A1 (en) * 1995-10-13 1997-04-14 Eri Inoue Pharmaceutical composition
WO1999051738A1 (en) 1998-04-03 1999-10-14 Hunan Medical University Human gap junction protein beta-4
WO1999051634A1 (en) 1998-04-03 1999-10-14 Hunan Medical University Human gap junction protein beta-3
AU6290299A (en) 1998-10-15 2000-05-01 E.I. Du Pont De Nemours And Company Polymers, containing a fluorocyclobutyl ring and their preparation
WO2004005883A2 (en) 2002-07-02 2004-01-15 The Johns Hopkins University Secreted and cytoplasmic tumor endothelial markers
JP3783200B2 (ja) * 2000-08-24 2006-06-07 株式会社加美乃素本舗 血管新生剤
US7263214B2 (en) 2002-05-15 2007-08-28 Ge Medical Systems Global Technology Company Llc Computer aided diagnosis from multiple energy images
WO2003096981A2 (en) 2002-05-15 2003-11-27 Seul, Kyung, Hwan Method of modulating angiogenesis
WO2004096277A1 (ja) * 2003-05-01 2004-11-11 Kyoto University 眼内血管新生疾患の予防又は治療剤
EP1624886A2 (en) * 2003-05-12 2006-02-15 Expressive Constructs, Inc. Methods for increasing cell and tissue viability
AU2005275062A1 (en) * 2004-07-14 2006-02-23 University Of Utah Research Foundation Netrin-related compositions and uses
KR101840445B1 (ko) 2005-02-03 2018-05-04 코다 테라퓨틱스 (엔지) 리미티드 항-코넥신 화합물 및 그의 용도
WO2006091930A2 (en) 2005-02-24 2006-08-31 Massachusetts Eye & Ear Infirmary Methods and compounds for promoting vessel regression
WO2007084895A2 (en) 2006-01-13 2007-07-26 The Research Foundation Of State University Of New York Peptide-based regulation of gap junctions
US20100004168A1 (en) * 2006-06-30 2010-01-07 The Johns Hopkins University Use of Crystallin For The Modulation of Angiogenesis
KR20100027091A (ko) 2006-11-15 2010-03-10 코다 테라퓨틱스, 인크. 상처 치유를 위한 개선 방법 및 조성물
CA2671724A1 (en) 2006-12-11 2008-06-19 The Board Of Trustees Of The Leland Stanford Junior University Alpha b-crystallin as a therapy for inflammation
WO2009012224A2 (en) 2007-07-13 2009-01-22 The Research Foundation Of State University Of New York Peptide-based regulation of gap junctions
EP2407175A1 (en) * 2007-09-07 2012-01-18 Meat & Livestock Australia Limited Agents with angiogenic and wound healing activity

Also Published As

Publication number Publication date
WO2009029991A1 (en) 2009-03-12
AU2008295449A1 (en) 2009-03-12
EP2190455A1 (en) 2010-06-02
JP2010538020A (ja) 2010-12-09
EP2407175A9 (en) 2012-02-29
US8404644B2 (en) 2013-03-26
US20100210531A1 (en) 2010-08-19
EP2190455A4 (en) 2010-11-24
NZ583803A (en) 2012-12-21
EP2407175A1 (en) 2012-01-18

Similar Documents

Publication Publication Date Title
JP5685773B2 (ja) 血管新生および創傷治癒活性がある薬剤
US9956252B2 (en) Purified amniotic membrane compositions and methods of use
CN102690344B (zh) 色素上皮衍生因子衍生的多肽对于促进干细胞增殖与伤口愈合的用途
CA2032059C (en) Wound treatment employing biologically active peptides
JP6703040B2 (ja) 角膜創傷治癒および眼表面疾患のためのヒスタチン
KR20010031266A (ko) 헤지호그류 폴리펩티드에 의해 상피 조직을 조절하는방법, 및 이와 관련된 제형 및 용도
JPH07502490A (ja) 殺菌性／透過性増大タンパク質および脂質担体を含有する組成物、その製造方法、およびそれらの使用
AU2013311714C1 (en) Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases
JP2023179739A (ja) 角膜の混濁および瘢痕化の予防および治療のための組成物および方法
JP2003534363A (ja) トランスジェニック非ヒト動物由来ヒト血清アルブミン含有化粧組成物
JP2025125558A (ja) 皮膚科障害の処置のための薬剤
US7592310B2 (en) Induction of antibiotic proteins and peptides by LAIT/sCD14-protein
CN1278184A (zh) 预防或治疗局部缺血性疾病的药剂
WO2013073968A2 (en) Agents for modulation of cell signalling
CN101300022A (zh) 抗真菌肽和其使用方法
TWI863205B (zh) 具傷口癒合功效之鱸魚胜肽及其組成物
JP2001010972A (ja) プロサポシン関連ペプチドからなる細胞保護剤
CN113727990B (zh) 短合成肽及其治疗视网膜退化性疾病和/或组织损伤的用途
WO2025156192A1 (zh) 一种靶向igf1r治疗主动脉瘤和主动脉夹层的方法
Harrington Age and cataract-related degradation of crystallins in human lenses
JPH03291238A (ja) 角膜障害治療剤
WO2007135781A1 (ja) エフリンｂ２の活性を高めるペプチド，その塩，医薬用組成物，治療用キット

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110905

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130509

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A072

Effective date: 20130716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131028

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140528

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140901

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140924

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141023

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141225

R150 Certificate of patent or registration of utility model

Ref document number: 5685773

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees